Cancer Vaccine Value Chain & Economics WSJ Analysis Benchmark

Vein-to-Vein 44 Days
P&S Spend / Pt $5,000
Total Cost / Pt $194,000
P&S Capture % 2.58%
P&S Total Market $75,000,000

Clinical Preset

Cohort & Commercialization

Annual Patient Cohort 15,000 pts
Vein-to-Vein Latency Target 42 Days

Picks & Shovels Pricing

Personalis Sequencing / Pt $3,200
Tempus AI Neoantigen Calling / Pt $1,800
Moderna mRNA Batch Synthesis $24,000
Merck Keytruda Combination Regimen $165,000

Data Audit & Handoff

Export audited per-patient cost waterfall and picks-and-shovels supplier margin breakdown.

End-to-End Neoantigen Pipeline Flow

Step 01: Biopsy
Surgical Excision & QC
Clinical Site
$0
4 Days Latency
Step 02: Genomics
Ultra-Deep WES/RNA-Seq
Personalis NeXT
$3,200
14 Days Latency
Step 03: ML Pipeline
HLA Calling & Epitopes
Tempus AI Engine
$1,800
4 Days Latency
Step 04: Synthesis
Custom mRNA-LNP Batch
Moderna (mRNA-4157)
$24,000
18 Days Latency
Step 05: Delivery
PD-1 + Vaccine Infusion
Merck (Keytruda)
$165,000
4 Days Latency

Vein-to-Vein Timeline & Latency Bottleneck Critical Bottleneck: Step 02

Biopsy Excision Projected Patient Attrition Risk: 4.2% First Infusion
Primary delay root: Tissue Biopsy & Ultra-Deep Whole Exome Sequencing Turnaround (approx. 14 of 44 days). Reducing sequencing sample prep by 4 days cuts drop-out risk by 1.6%.

Per-Patient Regimen Cost Allocation

Personalis (Genomics)
$3,200
Tempus AI (Algorithms)
$1,800
Moderna (mRNA-4157)
$24,000
Merck (Keytruda PD-1)
$165,000

Picks & Shovels Annual Market Projections Across Indications

Indication Cohort (pts) Personalis Rev Tempus AI Rev P&S Spend Pool Total Regimen Pool
Enjoy this tool? Build your own with Super